Intervacc AB (publ)

Stockholm Stock Exchange IVACC.ST

Intervacc AB (publ) Gross Profit Margin for the year ending December 31, 2023: -172.25%

Intervacc AB (publ) Gross Profit Margin is -172.25% for the year ending December 31, 2023, a -595.42% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Intervacc AB (publ) Gross Profit Margin for the year ending December 31, 2022 was 34.77%, a -70.83% change year over year.
Intervacc AB (publ) Gross Profit Margin for the year ending December 31, 2021 was 119.18%, a 22.69% change year over year.
Intervacc AB (publ) Gross Profit Margin for the year ending December 31, 2020 was 97.13%, a 309.55% change year over year.
Intervacc AB (publ) Gross Profit Margin for the year ending December 31, 2019 was 23.72%, a 12.49% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Stockholm Stock Exchange: IVACC.ST

Intervacc AB (publ)

CEO	Mr. Jonas Sohlman
IPO Date	April 7, 2017
Location	Sweden
Headquarters	Västertorpsvägen 135
Employees	15
Sector	Healthcare
Industries Vaccines Biotechnology Pet Food Pharmaceuticals

Description

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.

Key trends

Past 5 years